NASDAQ$VRNA
Verona Pharma plc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Verona Pharma's financial performance for Q4 2023 was reported, highlighting a net loss, increased SG&A expenses, and a decrease in R&D expenses.
Verona Pharma reported a net loss of $14.1 million for Q4 2023. The company's SG&A expenses increased due to commercialization preparations, while R&D expenses decreased due to the completion of the ENHANCE program.
- FDA accepted the New Drug Application for ensifentrine with a PDUFA target action date of June 26, 2024.
- Commercialization strategy advanced in preparation for the US launch of ensifentrine.
- A $400 million debt financing facility was secured to support commercialization and growth.
- Development of a fixed-dose combination formulation with ensifentrine and glycopyrrolate progressed.
Headline financials
Revenue & EPS history
Verona Pharma · Revenue · Quarterly
$0
Forward guidance
Verona Pharma anticipates a transformational year in 2024, with a focus on finalizing US launch preparations for ensifentrine and progressing development programs.
Tailwinds
- Potential FDA approval of ensifentrine by June 26, 2024.
- Planned US market launch of ensifentrine in the second half of 2024, if approved.
- Finalization of key launch activities including pricing, distribution, and patient services.
- Continued disease awareness campaign, "Unspoken COPD."
- Planned submission of an IND for a fixed-dose combination formulation in the second half of 2024.
Headwinds
- Uncertainty regarding FDA approval of ensifentrine.
- Risks associated with commercial launch and market adoption.
- Potential delays in development programs.
- Dependence on third-party manufacturers and suppliers.
- Competition from existing COPD treatments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q4 2023
+3.3%
Avg return
Earnings day
+7.2%
Avg return
5 days after
+5.6%
Avg return
30 days after
48%
12 / 25 earnings
Positive
+56.8%
Q2 2022
Best reaction
-14.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | -0.0% | -0.1% | +0.9% | |
| Q1 2025 | +6.4% | +5.6% | +12.5% | |
| Q4 2024 | +5.7% | +6.4% | +1.5% | |
| Q3 2024 | +9.7% | +10.2% | +14.0% | |
| Q2 2024 | +15.8% | +36.5% | +35.1% | |
| Q1 2024 | -0.2% | -6.8% | -18.4% | |
| Q4 2023 | +5.4% | -1.1% | -6.4% | |
| Q3 2023 | +7.6% | — | — | |
| Q2 2023 | -3.4% | — | — | |
| Q1 2023 | +7.1% | — | — | |
| Q4 2022 | -8.5% | — | — | |
| Q3 2022 | -5.8% | — | — | |
| Q2 2022 | +56.8% | — | — | |
| Q1 2022 | +3.8% | — | — | |
| Q4 2021 | -1.1% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q2 2021 | +3.9% | — | — | |
| Q1 2021 | -4.4% | — | — | |
| Q4 2020 | -0.1% | — | — | |
| Q2 2020 | +10.3% | — | — | |
| Q4 2019 | -14.7% | — | — | |
| Q4 2018 | -3.3% | — | — | |
| Q3 2018 | +2.1% | — | — | |
| Q4 2017 | -3.5% | — | — | |
| Q3 2017 | -4.2% | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro